ACUR
Acura Pharmaceuticals, Inc.
Set alert
- YTD
- -60.00%
- 1 year
- -60.00%
- Open
- 0.0004
- Prev close
- 0.0002
- Mkt cap
- 13.20K
- Vol
- 400
- Avg vol
- 1.54K
- EPS
- -0.01
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0004
- High
- 0.0004
- Forward P/E
- -1.26
- Beta
- 2.06
- Short ratio
- 0.73
- Inst. own
- 19.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 2, 2023
- 50-d avg
- 0.678571
- 200-d avg
- 0.966739
- 1y target
- 6.00
Key statistics
- Market cap
- 6.89M
- Enterprise value
- 8.78M
- Trailing P/E
- -0.70
- Forward P/E
- -1.26
- PEG ratio
- 0.00
- Price / sales
- 2.04
- Price / book
- 0.00
- EPS (TTM)
- -0.83
- Beta
- 2.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -291.24%
- Revenue (TTM)
- 3.38M
- Revenue growth
- 3.80%
- Free cash flow
- -5.25M
- Total cash
- 4.27M
- Total debt
- 6.19M
- Return on equity
- -238.90%
- Shares outstanding
- 11.88M
- Short % of float
- 1.20%
- 50-day average
- 0.678571
- 200-day average
- 0.966739
Analyst view
Consensus: buy
Next earnings
Jan 2, 2023
Expected Jan 2, 2023. Consensus EPS estimate -0.27.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 2, 2023 | Sep 1, 2022 | 0.00 | — | — | — |
| Nov 15, 2021 | Sep 1, 2021 | 0.00 | 0.00 | — | — |
| Aug 16, 2021 | Jun 1, 2021 | 0.00 | -0.01 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 26, 2015 | MLV & Co | up | Hold | Buy |
| May 27, 2014 | MLV & Co | down | Buy | Hold |
| Aug 13, 2013 | MLV & Co | init | — | Buy |
About Acura Pharmaceuticals, Inc.
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, researches, develops, and commercializes products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; Egalet Ltd.; and Egalet Corporation to manufacture and commercialize Oxaydo products worldwide. The company was founded in 1935 and is based in Palatine, Illinois.
- Sector
- Healthcare
- Industry
- Drug Delivery
- Country
- United States
- Website
- acurapharm.com
News
- Acura Pharmaceuticals (OTCMKTS:ACUR) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?
- Acura Pharmaceuticals (OTCMKTS:ACUR) Shares Pass Above Two Hundred Day Moving Average – Should You Sell?
- Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results
- Stocks That Hit 52-Week Highs On Tuesday
- 22 Biggest Mid-Day Losers For Thursday
Your note
Sign in to keep a note on ACUR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ROSS GEORGE K | Director | Option Exercise | Jan 2, 2017 | 11,565 |
| SEISER ROBERT A | Officer | Option Exercise | Feb 6, 2017 | 22,490 |
| SKELLY WILLIAM G | Director | Option Exercise | Jan 2, 2017 | 28,345 |
| THANGARAJ IMMANUEL | Director | Option Exercise | Jan 2, 2017 | 23,812 |
| WESSON BRUCE F | Director | Option Exercise | Jan 2, 2017 | 58,670 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Essex Woodlands Health Ventures | 16.46% | 1,956,397 | 1.51M | Dec 30, 2016 |
| Deerfield Management | 8.63% | 1,025,641 | 789.74K | Dec 30, 2016 |
| Vanguard Group, Inc. (The) | 1.65% | 195,943 | 150.88K | Dec 30, 2016 |
| Renaissance Technologies, LLC | 0.95% | 113,220 | 87.18K | Dec 30, 2016 |
| Sabby Management, LLC | 0.87% | 103,444 | 79.65K | Dec 30, 2016 |
| KCG Holdings, Inc. | 0.38% | 44,565 | 34.31K | Dec 30, 2016 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.75% | 89,117 | 142.59K | Sep 29, 2016 |
| Vanguard Total Stock Market Index Fund | 0.52% | 61,759 | 98.81K | Sep 29, 2016 |
| Fidelity Extended Market Index Fund | 0.16% | 18,759 | 17.26K | Nov 29, 2016 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.08% | 9,859 | 9.07K | Nov 29, 2016 |
| Schwab Capital Trust-Total Stock Market Index Fund | 0.04% | 4,180 | 8.11K | Jul 30, 2016 |
| Quantitative Master Series Tr-Extended Market Index Series | 0.03% | 3,204 | 5.13K | Sep 29, 2016 |